JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Collier, T. L.
Right arrow Articles by Bergmann, S. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Collier, T. L.
Right arrow Articles by Bergmann, S. R.
Journal of Nuclear Medicine Vol. 43 No. 12 1707-1714
© 2002 by Society of Nuclear Medicine

Basic Science Investigations

Synthesis and Initial Evaluation of 17-11C-Heptadecanoic Acid for Measurement of Myocardial Fatty Acid Metabolism

T. Lee Collier, PhD1,2, Yuying Hwang, PhD1, Ravichandran Ramasamy, PhD1, Robert R. Sciacca, EngScD1, Kathleen T. Hickey, EdD1, Norman R. Simpson, BS2 and Steven R. Bergmann, MD, PhD1,2

1 Division of Cardiology, Department of Medicine, College of Physicians and Surgeons of Columbia University, New York, New York
2 Department of Radiology, College of Physicians and Surgeons of Columbia University, New York, New York

Fatty acid oxidation defects are being increasingly identified as causes of abnormal heart function and sudden death in children. Children with medium-chain acyl-coenzyme A (acyl-CoA) dehydrogenase defects can metabolize fatty acids labeled in the carboxylic acid end of the compound. Accordingly, our goal was to label a long-chain fatty acid in the {omega}-position and evaluate its myocardial kinetics. Methods: Heptadecanoic acid, a 17-carbon fatty acid, was labeled in the C-17 position with 11C by the general process of coupling 11C-methyliodide to t-butyl-15-hexadecanoate. Yield was ~5%–10% end-of-bombardment. Subsequently, evaluation studies were performed on isolated perfused rat hearts and in intact, anesthetized dogs. The myocardial uptake and efflux of 17-11C-heptadecanoic acid were compared with those of 1-11C-palmitate. Results: With the exception of delayed efflux of tracer reflecting the temporal delay for ß-oxidation, the washout of 17-11C-heptadecanoic acid from the heart mirrored that of 1-11C-palmitate in isolated rat hearts and in intact dogs with PET. Conclusion: 17-11C-Heptadecanoic acid may be a useful tracer for the identification of defects in fatty acid metabolism in subjects with medium- and short-chain fatty acid oxidation defects.

Key Words: fatty acid metabolism • inherited defects • fatty acid oxidation disorders • myocardial metabolism






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2002 by the Society of Nuclear Medicine.